SREBF2 and in situ carcinoma: For oral squamous cell carcinoma (OSCC), QUE inhibited cholesterol metabolism by inhibiting the AGR2/AKT/SREBP2 signaling pathway, enhancing CIS sensitivity to CIS-resistant CAL-27 cells (60).